Goutham Sunny, Resident Doctor at The Gujarat Cancer and Research Institute, shared a post on X:
“KMT2A-rearranged AML responds well to intensive chemo (CR/CRi 81–100%, 5-yr OS 66%), but outcomes remain poor with low-intensity treatment (CR/CRi 33–61%, OS 7%), especially with N/KRAS mutations—highlighting need for better therapies.”
More posts featuring Acute Myeloid Leukemia on OncoDaily.